New Market Study on IVIG Market With Growth & Revenue Analysis By Leading Key Players, Baxter International, CSL Ltd., Grifols S.A, Octapharma AG, Kedrion Biopharma, LFB group, Biotest AG and Many Others

The global intravenous immunoglobulin (IVIG) market was valued at $7,861 million in 2015 and is projected to reach $12,632 million by 2022, registering a CAGR of 7.1% from 2016 to 2022. Immunoglobulins (IGs) are glycoproteins produced by plasma cells in response to antigens, which are considered as foreign bodies in a host system. They are highly complex entities that exhibit high specificity in their action. IGs are obtained from blood by fractionation process, and eventually purified for use in therapeutic and non-therapeutic applications. Various classes of immunoglobulin including IgG, IgA, and IgM are used for the treatment of immunological and neurological diseases.

Rise in prevalence of autoimmune disorders across the globe and surge in demand for intravenous immunoglobulin for treating neurological disorders supplement the growth of the IVIG market.

Download [PDF] Report Sample @ https://www.alliedmarketresearch.com/request-sample/325

Immunoglobulin (IG) is a plasma-derived product, which is obtained from the serum of healthy donors. The isolated plasma product is clinically treated and purified to IG, which can be further used in the treatment of patients with antibody deficiency. Intravenous immunoglobulin (IVIG) is used in various fields such as hematology, immunology, neurology, dermatology, nephrology, ophthalmology, and rheumatology.

The prevalence of a host of antibody deficiency disorders such as common variable immune deficiency (CVID), specific antibody deficiency, and hypogammaglobulinemia, increase in immunoglobulin indications, improved production & purification processes, growth in awareness toward antibody deficiency, and rare immune disorders among patient population drive the growth of the global IVIG market. However, stringent government regulations towards immunoglobulin products and high risk of side effects owing to the use of intravenous immunoglobulin are expected to hamper the growth of the market.

Based on application segment, hypogammaglobulinemia held the largest market share in 2015 and is anticipated to continue this trend in near future. Large patient population, lack of effective substitute treatment, and early adoption of immunoglobulin for the treatment of hypogammaglobulinemia are expected to boost the growth of this segment.

In 2015, North America accounted for the largest share in the global market, followed by Asia-Pacific. The major factors responsible for the growth of the IVIG market in these regions include high adoption rate in developed and populous countries such as Japan and the U.S. and coupled by the presence of large plasma production facilities.

Get Customized Report @ https://www.alliedmarketresearch.com/request-for-customization/325

The key companies profiled in the report include Baxter International Inc; CSL Ltd., Grifols, S.A.; Octapharma AG, Kedrion Biopharma Inc., LFB Group, Biotest AG, China Biologics Products, Inc.; Shire (Baxalta); and Bayer AG.

Other players in the value chain include Hualan Biological Engineering Inc., Omrix Biopharmaceuticals Ltd., Behring GmbH, Shanghai RAAS Blood Products Co., Ltd., Option Care Enterprises, Inc., ADMA Biologics, Inc., and BioScrip, Inc.

Key Benefits for Intravenous Immunoglobulin (IVIG) Market:

•The report provides an in-depth analysis of the global IVIG market along with the current trends and future estimations to elucidate the imminent investment pockets.
•A comprehensive analysis of the factors that drive and restrict the market growth is provided in this study.
•The report provides a detailed quantitative analysis of the industry from 2016 to 2022 to assist stakeholders to capitalize on the prevailing market opportunities.
•An extensive analysis of the key segments of the industry helps understand the trends in the global IVIG market.
•Key players and their strategies are provided to understand the competitive outlook of the industry.

Access Full Summery @ https://www.alliedmarketresearch.com/press-release/intravenous-immunoglobulin-IVIG-market.html

About us

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

Contact

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

This release was published on openPR.